Renaissance Technologies’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-2,720,360
Closed -$6.12M 3857
2020
Q3
$6.12M Sell
2,720,360
-3,333,700
-55% -$9.52M 0.01% 1459
2020
Q2
$21.7M Sell
6,054,060
-3,372,100
-36% -$12.2M 0.02% 772
2020
Q1
$35.8M Sell
9,426,160
-4,832,400
-34% -$15.9M 0.03% 497
2019
Q4
$42.9M Buy
+14,258,560
New +$37.1M 0.03% 590

Other funds holding BMY.RT

Renaissance Technologies's BMY.RT Position: Q4 2020 in Review

Renaissance Technologies sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q4 2020, closing a stake of 2,720,360 shares — an estimated $6.12M sold.

Renaissance Technologies first reported a position in BMY.RT in Q4 2019 and held it in 4 quarters. The position peaked at $42.9M in Q4 2019. 546 funds tracked by Wall St. Rank hold BMY.RT as of Q4 2020.

  • Renaissance Technologies reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q4 2020 after selling out during the quarter.
  • Renaissance Technologies sold 2,720,360 Bristol-Myers Squibb Company Contingent Value Rights shares in Q4 2020, an estimated $6.12M.
  • Renaissance Technologies first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 4 quarters.
  • Renaissance Technologies's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $42.9M in Q4 2019.
  • 546 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q4 2020.

Based on Renaissance Technologies's 13F filing for Q4 2020, filed 10 Feb 2021.